Summary We have correlated the morphological features of 30 human thyroid carcinomas with the cellular localisation of insulin-like growth factor 1 (IGF-1) mRNA and IGF-1 receptor peptide using in situ hybridisation with digoxigenin-labelled oligoprobes and immunohistochemistry. Four of the five follicular carcinomas studied showed a consistent, uniform, strong positivity for IGF-I mRNA in tumour cells compared with weakly positive surrounding normal follicular tissue and negative stroma. The majority of papillary carcinomas showed weak to moderate epithelial positivity for IGF-I mRNA and negative stroma. Immunohistochemistry for IGF-1 receptor showed moderate positivity confined to the tumour epithelial cells in both follicular and the majority of papillary carcinomas. However, in a subgroup of papillary carcinomas characterised by a diffuse stromal lymphoid infiltration (n = 5), the stromal cells showed a much stronger reactivity for IGF-1 mRNA than the tumour or background thyroid, and the tumour cells showed a uniformly high level of immunoreactivity for IGF-1 receptor. These results are compatible with the growth of the papillary carcinoma in these cases being the result of a symbiotic relationship between the stromal lymphoid cells and the tumour epithelium with the lymphoid cells responding to an antigen produced by the tumour cells and the tumour cells responding to a growth factor produced by the lymphoid infiltrate. We suggest that this mechanism may be important in other tumours. regularly associated with a widespread lymphoid infiltrate.
The local production of growth factors is important for the control of normal and neoplastic cell growth. Acquisition of autocrine secretion of growth factors combined with expression of their receptors, is thought to play a significant role in neoplastic transformation (Daughaday, 1990) . The key factor involved in the growth of the normal human thyroid follicular cell is thyroid-stimulating hormone (TSH), but it has been shown in culture that insulin-like growth factor 1 (IGF-1) is necessary for the growth response to TSH (Williams et al., 1987) . Autocrine production of IGF-1 has also been suggested as one of the mechanisms involved in growth control of human follicular adenomas (Williams et al., 1988 . Many other growth factors have also been implicated in thyroid growth, but IGF-1 and TSH are probably the most important in normal growth. In vivo, the maintenance of organised tissue architecture requires communication between epithelium and stroma and their interaction may be important for the role of IGF-1 in thyroid growth. However the relative roles of follicular cells and stroma in the production of IGF-1 in thyroid tumours has not been determined. In view of its documented importance in thyroid follicular cell growth in vitro, it is likely that IGF-1 plays an important role in the control of coordinated growth of the thyroid in vivo, whether in normal or neoplastic tissue.
Few previous studies have been carried out to localise IGF-1 production in the thyroid in vivo. Interpretation of immunocytochemistry for IGF-I peptide is complicated by the possibility of antibody cross-reaction with the structurally similar insulin-like growth factor 2 (IGF-2; Ollis et al., 1989) . A previous study using radioactive in situ hybridisation (ISH) in normal breast tissue showed that IGF-I mRNA was localised to the stroma, but in neoplasia it was localised to the tumour cells, suggesting a switch to autocrine production during the neoplastic process (Yee et al., 1989) . However, accurate cellular localisation has proved to be difficult using radioactively labelled probes. We have therefore used a nonradioactive approach which allows good cellular localisation and ease of differentiation between stromal and epithelial staining.
We have recently developed a sensitive technique using digoxigenin-labelled oligonucleotide probes to demonstrate mRNA in routine, paraffin-embedded sections from archival material (Thomas et al., 1993; Neonakis et al., 1994) . Previous work, using oligoprobes complementary to IGF-1 mRNA in the mouse have shown that the follicular cell is the source of IGF-1 in the growing mouse thyroid (IGFR) . These antibodies have been fully characterised; they recognise distinct epitopes and neither antibody shows significant cross-reactivity with either the insulin receptor or IGF-binding proteins (Soos et al., 1992) . A dilution profile for histochemical studies was carried out on a known positive tissue (urothelium). Thyroid sections were incubated overnight at 4°C in antibody at a dilution of 1: 500. A standard indirect peroxidase technique was used to localise bound antibody using 3,3'-diaminobenzidine (DAB) as the reporter molecule. Negative controls included omission of primary antibody and use of an irrelevant mouse antibody of the same IgG subclass (anti-bromodeoxyuridine, Sigma, Poole, Dorset, UK).
in situ hybridisation Two 30 mer antisense cDNA oligonucleotide sequences complementary to the regions coding for amino acids 1-9 and 72-81 of IGF-I mRNA were used to detect IGF-1 mRNA. The first probe showed 100% homology to the human sequence and 97% to mouse and the second 97% homology to man and 100% to mouse. Both sequences are shared by the transcripts lA -and iB, showing no significant homology with IGF-2 mRNA or any other known sequence and have been used with success for ISH studies in mouse thyroid . The probes were labelled both 5' and 3' with digoxigenin (R&D Systems, Abingdon, UK). The expression of K and A light chain mRNA was also studied by ISH, using previously characterised cocktails of probes (29 mer and 30 mer), labelled 5' and 3' with digoxigenin (R&D Systems) at a concentration of 0.05 ng lil'.
The ISH technique used has been described in detail elsewhere (Thomas et al., 1993) . Briefly, sections were digested in 1 lag ml-' proteinase K for 30 min at 37°C, preincubated in hybridisation buffer for 1 h at 37°C and hybridised overnight in 45 ;l of the same buffer containing 0.5 ng fL of each IGF-1 probe. After washing in graded concentrations of SSC to remove unbound probe, bound probe was detected by alkaline phosphatase-linked antidigoxigenin antibody (1:500) and standard histochemistry using nitroblue tetrazolium (NBT) as the reporter molecule. Control sections were hybridised in the absence of labelled probe or with the same concentration of a 5' 3' doublelabelled irrelevant probe, with similar length and GC content to the test probe (EBER 1 mRNA; Khan et al., 1992) . As a measure of reproducibility of the technique sections of known positive control tissues for IGF-l mRNA (mouse thyroid and parathyroid) and EBER 1 mRNA (infectious mononucleosis lymph node) were included each time the technique was carried out.
Results
Five carcinomas showed the morphological features of follicular carcinomas (Figure la). Four were trabecular or follicular in structure, one of the four was widely invasive. One tumour showed a solid, poorly differentiated pattern of growth. Immunohistochemistry and ISH was positive for thyroglobulin and negative for calcitonin in all tumours.
The 25 remaining tumours showed the morphological features of papillary carcinoma. Sixteen showed typical features, six were follicular variants, two showed mainly oxyphil differentiation and one was classified as a diffuse sclerosing variant. Five of the tumours with predominantly papillary architecture showed widespread heavy lymphocytic infiltrate within the fibroblastic core of papillae (Figure 2a) . The infiltrate appeared to be non-destructive and consisted mainly of plasma cells. The remaining tumours showed little or no lymphoid infiltrate.
In situ hybridisation Sections from all tumours studied were uniformly positive on hybridisation with the oligo(dT) probe and negative on hybridisation with EBER 1 mRNA probe. Both IGF-I probes showed a similar staining pattern.
Normal thyroid follicular epithelium removed with the tumours showed considerable intercellular heterogeneity for IGF-I mRNA positivity by ISH (Figure 2b ). The overlying follicular epithelium showed only weak to moderate staining. Further studies using digoxigenin-labelled oligoprobes for K and A light chain mRNA revealed that the lymphoplasmacytic infiltrate was polyclonal.
Immunocytochemistry No significant staining was observed when slides were incubated without primary antibody or with a control antibody. Both IGF-I receptor antibodies used gave similar results.
Immunohistochemistry for IGF-1 receptor gave uniformly weak to negative results in both normal follicular epithelium and stroma. In all cases of follicular carcinoma, IGF-1 receptor immunohistochemistry showed a moderate and diffuse positivity in tumour cells, with a mainly cytoplasmic distribution. Surrounding tissue stromal cells were mostly free of immunostaining. The semiquantitative results for both the normal and the neoplastic thyroid are shown in Table I . Follicular epithelial cells in the majority (12/20) of the papillary carcinomas lacking a lymphocytic infiltrate were weakly positive on immunocytochemistry for IGF-I receptor. The remainder (8/20) were moderately positive. There was no demonstrable immunopositivity for IGF-1 receptor in tumour stroma. In contrast, the follicular epithelium of papillary carcinomas which contained a heavy lymphoplasmacytic infiltrate within the fibroblastic core were uniformly strongly positive for IGF-1 receptor (Figure 2c ).
Discussion
We have used ISH to localise IGF-l mRNA and immunocytochemistry to localise IGF-l receptor peptide in differentiated thyroid carcinomas. We chose to use an approach using ISH with oligonucleotide probes for localisation of IGF-I as doubts have previously been raised about the specificity of a number of IGF-1 antibodies because of crossreactivity with IGF-2 (Ollis et al., 1989), and because ISH Interdependence of epithelium and stroma in PTC MH Takahashi et al Interdependence of epithelium and stroma in PTC MH Takahashi et al 816 gives more direct information on the cellular site of production. In the normal thyroid there is a heterogeneous distribution of IGF-1 mRNA in follicular cells, with virtually no demonstrable stromal positivity. These findings are similar to those we have already observed in the adult mouse thyroid . There is also a very low expression of the IGF-I receptor in normal follicular epithelium. In contrast, follicular epithelium in four of the five follicular carcinomas showed a uniformly high level of IGF-1 mRNA expression, and weak positivity for the receptor peptide on immunohistochemistry. This adds support to the hypothesis that IGF-I is an important growth factor for thyroid follicular cells and that autocrine secretion may be implicated in thyroid follicular carcinogenesis . The weak positivity observed on immunocytochemistry may be due to down-regulation of the receptor as has been shown to occur in cell culture when IGF-l peptide is present in the culture medium (Werther et al., 1989) .
In the majority of papillary carcinomas, there is weak to moderate positivity for IGF-I mRNA in the epithelial cells, and a low level of IGF-1 receptor peptide by immunocytochemistry. Interestingly, a subset of papillary carcinomas which have a marked lymphoplasmacytic infiltrate showed a uniformly strong positivity for IGF-1 receptor peptide in the tumour cells on immunocytochemistry. The low level of IGF-1 mRNA demonstrated by ISH in the epithelial cells did not significantly differ from that observed in the papillary tumours lacking infiltrate. However, the polyclonal lymphoplasmacytic infiltrate was strongly positive for IGF-l mRNA. While an increased content of IGF-1 mRNA does not prove that increased translation is taking place, particularly as this is in part regulated by post-transcriptional mechanisms (Hepler et al., 1990) . These results suggest that IGF-l produced by the stromal plasma cell infiltrate may stimulate the growth of the overlying follicular epithelium via the IGF-1 receptor present in increased amounts on the epithelial cells.
These studies show that the follicular cell is the main source of intrathyroid IGF-1 in both normal human thyroid and follicular carcinoma, and provide evidence that epithelial cells in papillary tumours produce this factor to a lesser extent than the cells of follicular tumours. This suggests that different growth factor pathways may be operative in papillary thyroid carcinoma compared with follicular carcinoma; an observation in keeping with the differential oncogene expression (Bongarzone et al., 1989; Lemoine et al., 1989) . It has been suggested that epidermal growth factor (EGF) receptor and transforming growth factor alpha TGF-o may be involved in an autocrine loop in papillary carcinoma (Haugen et al., 1992) , but it is not clear whether this mechanism is specific to papillary carcinoma. It has been suggested previously that the subset of papillary tumours which harbour a non-destructive lymphoplasmacytic infiltrate may be a distinct entity with a different aetiology (Harach et al., 1985) . Our finding of high levels of IGF-1 mRNA in the plasma cells in association with increased IGF-1 receptor peptide in the tumour cells demonstrable by immunocytochemistry are of particular interest. IGF-1 binding proteins, are important regulators of IGF-I activity (Rechler and Nissley, 1990) . A recent study in the rat has shown that three binding proteins are present, and that their individual levels vary during hyperplasia and involution (Phillips et al., 1994) . It is clear therefore that changes in binding protein content of the thyroid may have a considerable effect on the ability of newly produced IGF-l to influence epithelial growth. We have not carried out studies of the level of different binding proteins in these tumours, nor have we carried out any biological studies on the relationship between the tumour cells and the stroma as all the material available to us is fixed. However, we suggest that the most likely interpretation of the observations is that there is a symbiotic relationship between the tumour and the stromal infiltrate, with the tumour cells producing an antigen which stimulates the lymphoid infiltrate, and the lymphoid cells producing IGF-1 which stimulates the growth of the tumour epithelial cells. IGF-I is a known growth factor for thyroid follicular cell lines derived from papillary carcinomas. Some papillary carcinoma cell lines have been shown to express IGF-1 receptor and to proliferate in response to the supply of exogenous IGF-l in the medium. A small amount of IGF-1 mRNA was also detected using reverse transcriptase-polymerase chain reaction (RT-PCR) in one cell line. (Onoda et al., 1992) . Although IGF-I has been identified as an important growth factor for thyroid cells, it is clear that the regulation of IGF-l is complex, and may be modulated not only by its binding proteins, but also by other factors. In addition, lymphoid cells are known to produce a variety of growth factors including interleukins which can stimulate epithelial cell growth.
Lymphoid infiltration occurs in a variety of tumours and is usually interpreted as a cytotoxic immune response to a tumour antigen. In some tumours the presence of a lymphoid infiltrate may be a good prognostic indicator, for example in colonic carcinoma (Jass et al., 1986) and nodular malignant melanoma (Cook, 1994) . In the particular subgroup of thyroid papillary carcinomas we have studied, the lymphoid infiltrate is mostly composed of plasma cells, and confined to the stroma, with virtually no evidence of lymphocytes crossing the basement membrane or destruction of tumour cells. The possibility that lymphoid stromal cells may be producing growth factors which stimulate the growth of the epithelial cells is clearly worth considering in any tumour with a diffuse lymphoid infiltrate. In the thyroid of course, normal follicular cells are stimulated to hyperfunction and growth by antibodies in Graves' disease. In the salivary gland the so called adenolymphoma or Warthin's tumour is an obvious candidate for dependence of the tumour epithelium on a factor produced by the lymphoid stroma. One important tumour where there may be a link is nasopharyngeal carcinoma. Here the admixture is more intimate than in the tumours we have studied.
The use of ISH to localise cells containing growth factor mRNAs provides valuable information on the presumed site of production. The parallel demonstration of cell content of receptor by immunohistochemistry suggests that the cell concerned may be able to respond to the appropriate signal. Together they can be used to propose a hypothesis of autocrine or paracrine growth control, and to point the way to appropriate in vitro studies. It is important to establish extra cellular mechanisms of growth control, not only to increase our knowledge of the way tumour growth is mediated but also because of the possibility of therapy directed to the infiltrate rather than the tumour cells.
